- Home
- PSBD vs KURA Comparison
PSBD vs KURA Comparison
Compare PSBD & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSBD
- KURA
- Stock Information
- Founded
- PSBD 2009
- KURA 2014
- Country
- PSBD United States
- KURA United States
- Employees
- PSBD N/A
- KURA N/A
- Industry
- PSBD
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSBD
- KURA Health Care
- Exchange
- PSBD Nasdaq
- KURA Nasdaq
- Market Cap
- PSBD 452.3M
- KURA 492.9M
- IPO Year
- PSBD 2024
- KURA N/A
- Fundamental
- Price
- PSBD $13.81
- KURA $6.42
- Analyst Decision
- PSBD Buy
- KURA Strong Buy
- Analyst Count
- PSBD 4
- KURA 12
- Target Price
- PSBD $14.13
- KURA $24.50
- AVG Volume (30 Days)
- PSBD 47.7K
- KURA 1.2M
- Earning Date
- PSBD 05-07-2025
- KURA 05-01-2025
- Dividend Yield
- PSBD 12.27%
- KURA N/A
- EPS Growth
- PSBD N/A
- KURA N/A
- EPS
- PSBD N/A
- KURA N/A
- Revenue
- PSBD N/A
- KURA $67,991,000.00
- Revenue This Year
- PSBD N/A
- KURA $171.90
- Revenue Next Year
- PSBD N/A
- KURA $60.51
- P/E Ratio
- PSBD N/A
- KURA N/A
- Revenue Growth
- PSBD N/A
- KURA N/A
- 52 Week Low
- PSBD $11.51
- KURA $5.41
- 52 Week High
- PSBD $16.85
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- PSBD 55.61
- KURA 55.97
- Support Level
- PSBD $13.69
- KURA $5.56
- Resistance Level
- PSBD $14.22
- KURA $5.84
- Average True Range (ATR)
- PSBD 0.44
- KURA 0.36
- MACD
- PSBD 0.03
- KURA 0.05
- Stochastic Oscillator
- PSBD 51.27
- KURA 89.52
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.